CRINETICS PHARMACEUTIC

Crinetics Pharmaceuticals Provides Update on CRN04777 Program

28 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

22 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

14 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Nov 2022 15:30:43 By Nasdaq GlobeNewswire

Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

13 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Oct 2022 15:57:25 By Nasdaq GlobeNewswire

Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

06 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer

03 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

08 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

06 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism

02 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

12 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Aug 2022 15:44:12 By Nasdaq GlobeNewswire

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

04 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jul 2022 16:09:22 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2022 15:30:47 By Nasdaq GlobeNewswire

Crinetics Presents Clinical and Research Results at ENDO 2022

08 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

07 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

25 May 2022 06:00:00 By Nasdaq GlobeNewswire